Early experience with active surveillance in low-risk prostate cancer treated

Korean Journal of Urology

Volumn 55, Issue 3, 2014, Pages 167-171

  Ha, Ji Yong ^a   Kim, Byung Hoon ^a   Park, Choal Hee ^a   Kim, Chun Il ^a  

^a Keimyung University School of Medicine   (South Korea)

Author keywords

Needle biopsy; Prostate specific antigen; Prostatic neoplasms; Watchful waiting

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DISEASE SURVEILLANCE; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; RISK; VERY ELDERLY;

EID: 84896444459     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2014.55.3.167     Document Type: Article

References (29)

1. Park SK, Sakoda LC, Kang D, Chokkalingam AP, Lee E, Shin HR, et al. Rising prostate cancer rates in South Korea. Prostate 2006;66:1285-91.
2. The statistics report: the incidence of cancer on 1999-2011 and the survival rate on 2012 [Internet]. Goyang: National Cancer Center; [cited 2012 Dec 1]. Available from: http://www.ncc.re.kr.
3. Carter HB, Walsh PC, Landis P, Epstein JI. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 2002;167:1231-4.
4. Choo R, Klotz L, Danjoux C, Morton GC, DeBoer G, Szumacher E, et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002;167:1664-9.
5. Klotz L. Active surveillance for favorable-risk prostate cancer: who, how and why? Nat Clin Pract Oncol 2007;4:692-8.
6. Lawrentschuk N, Klotz L. Active surveillance for favorable-risk prostate cancer: a short review. Korean J Urol 2010;51:665-70.
7. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28:126-31.
8. van den Bergh RC, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS, et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 2009;55:1-8.
9. Kakehi Y, Kamoto T, Shiraishi T, Ogawa O, Suzukamo Y, Fukuhara S, et al. Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn J Clin Oncol 2008;38:122-8.
10. Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 2008;112:2664-70.
11. Berglund RK, Masterson TA, Vora KC, Eggener SE, Eastham JA, Guillonneau BD. athological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol 2008;180:1964-7.
12. Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B, Manoharan M. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int 2008;101:165-9.
13. Reynard J, Brewster S, Biers S. Oxford handbook of urology. PSA derivatives and kinetics: free-to-total, density, velocity, and doubling time. Oxford: Oxford University Press; 2010.
14. Fowler FJ Jr, McNaughton Collins M, Albertsen PC, Zietman A, Elliott DB, Barry MJ. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA 2000;283:3217-22.
15. Barocas DA, Cowan JE, Smith JA Jr, Carroll PR; CaPSURE Investigators. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol 2008;180:1330-4.
16. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-74.
17. Bastian PJ, Mangold LA, Epstein JI, Partin AW. Characteristics of insignificant clinical T1c prostate tumors: a contemporary analysis. Cancer 2004;101:2001-5.
18. Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, et al. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 2012;62:976-83.
19. Fradet V, Kurhanewicz J, Cowan JE, Karl A, Coakley FV, Shinohara K, et al. Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging. Radiology 2010;256:176-83.
20. Afaq A, Koh DM, Padhani A, van As N, Sohaib SA. Clinical utility of diffusion-weighted magnetic resonance imaging in prostate cancer. BJU Int 2011;108:1716-22.
21. Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010;28:2810-6.
22. Whitson JM, Porten SP, Hilton JF, Cowan JE, Perez N, Cooperberg MR, et al. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol 2011;185:1656-60.
23. Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011;29:2185-90.
24. van As NJ, Norman AR, Thomas K, Khoo VS, Thompson A, Huddart RA, et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 2008;54:1297-305.
25. Cooperberg MR, Carroll PR, Klotz L. Active surveillance for prostate cancer: progress and promise. J Clin Oncol 2011;29:3669-76.
26. Chung JS, Han BK, Jeong SJ, Hong SK, Byun SS, Choe G, et al. Pathologic outcome of unilateral low risk prostate cancers on multicore prostate biopsy after radical prostatectomy. Korean J Urol 2008;49:874-8.
27. Lee SE, Kim DS, Lee WK, Park HZ, Lee CJ, Doo SH, et al. Application of the Epstein criteria for prediction of clinically insignificant prostate cancer in Korean men. BJU Int 2010;105:1526-30.
28. Kim SC, Hong JH, Song K, Jeong IG, Song C, Kim CS, et al. Predictive factors for upgrading or upstaging in biopsy gleason score 6 prostate cancer. Korean J Urol 2009;50:836-42.
29. Ahn HJ, Ko YH, Jang HA, Kang SG, Kang SH, Park HS, et al. Single positive core prostate cancer in a 12-core transrectal biopsy scheme: clinicopathological implications compared with multifocal counterpart. Korean J Urol 2010;51:671-6.